LENSAR
- Company typePublic
- Founded2010
- HeadquartersOrlando, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
LENSAR firmographics
Firmographics- Name
- LENSAR
- Legal name
- LENSAR, Inc.
- Website
- https://lensar.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
LENSAR industry classification
Industry- Product category
- Ophthalmic Surgical Laser Systems
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)
- akta.pro secondary industry
- Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG)
Keywords
Where LENSAR is headquartered
LocationHeadquarters
- HQ city
- Orlando
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LENSAR business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
Revenue model
- System Sales (Capital Equipment): Sale of ALLY Robotic Cataract Laser Systems and LENSAR Laser Systems to eye surgery centers and hospitals. Represents the non-recurring portion of revenue, though declining due to market uncertainty around terminated Alcon merger.
- Recurring Revenue (Service/Consumables): Recurring revenue from service contracts, disposables, and consumables associated with installed laser systems. Growing as installed base expands - reached 94% of total revenue in Q1 2026 ($12.6M), up 9% year-over-year.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise capital equipment pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
LENSAR product offering
Product offeringCore offering
LENSAR designs, manufactures, and sells femtosecond cataract laser systems — the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System — to ophthalmic surgeons and eye surgery centers for refractive cataract surgery. Revenue comes from the sale of these capital equipment systems plus recurring service contracts and consumables tied to an installed base of approximately 440 systems. The company complements its hardware with proprietary imaging and software (Streamline, Cataract Density Imaging, IntelliAxis Refractive Capsulorhexis, Iris Registration) that automate surgical planning and precision.
Product overview
LENSAR is a medical technology company specializing in femtosecond laser systems for refractive cataract surgery. The product portfolio centers on two core platforms: the LENSAR Laser System and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System serves as the foundational femtosecond laser platform with proprietary imaging technologies including Cataract Density Imaging, Scheimpflug imaging, and 3-D confocal structured illumination. The ALLY System represents the next generation, combining dual-pulse femtosecond laser technology with advanced imaging in a single compact system. Both platforms share key software features including Streamline upgrades (I through IV), IntelliAxis Refractive Capsulorhexis for toric IOL alignment, Iris Registration for cyclorotation adjustment, and arcuate incision planning. The systems integrate with pre-operative diagnostic devices including Pentacam, Cassini, Nidek OPD-Scan III, and Topcon Aladdin for wireless data transfer.
Differentiator
Problem solved
Functional benefit
Brands
- ALLY: ALLY Adaptive Cataract Treatment System - FDA-cleared robotic cataract laser system combining dual-pulse femtosecond laser with advanced imaging technology
- LENSAR Laser System
- Streamline
- IntelliAxis Refractive Capsulorhexis
- Cataract Laser with Augmented Reality
Products and services
- ALLY Adaptive Cataract Treatment System FDA-cleared robotic cataract laser system that combines dual-pulse femtosecond laser technology with advanced imaging in a single compact system to enable sterile FLACS procedures for ophthalmic surgeons and eye surgery centers.
- LENSAR Laser System Premier femtosecond laser cataract treatment platform with proprietary imaging including Scheimpflug imaging, Cataract Density Imaging, and IntelliAxis Refractive Capsulorhexis, designed for refractive cataract surgeons seeking superior outcomes and faster visual recovery.
- Streamline IV Software Upgrade Software upgrade for the LENSAR Laser System that adds IntelliAxis Refractive Capsulorhexis, enabling precise toric IOL alignment by marking the steep axis on the capsular rim and eliminating parallax from corneal markings.
- Streamline III Software Upgrade Software upgrade for the LENSAR Laser System that expanded wireless pre-operative diagnostic integration to support successful refractive outcomes.
- IntelliAxis Refractive Capsulorhexis Proprietary technology incorporated into the LENSAR and ALLY platforms that places small tabs on the capsular rim during capsulorhexis to clearly identify the intended axis for precise toric IOL alignment.
- Cataract Density Imaging Proprietary imaging module that automatically grades cataract density (I-V), identifies nucleus location and lens layers, and enables adaptive fragmentation patterns optimized for tissue-specific treatment and reduced phaco energy.
- Iris Registration Automated software module that confirms image compatibility at capture, detects eye cyclorotation, and automatically adapts treatment to replace less precise preoperative manual ink markings for increased laser precision.
Quantifiable outcome
- Up to 100% of patients within 0.50D for toric IOL treatment guided by IntelliAxis
- +10 more outcomes
Companies that use LENSAR
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles1 record
LENSAR technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability5 records
Feature10 records
LENSAR partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AlconterminatedPlanned acquisition of LENSAR by Alcon for approximately $356-430 million was mutually terminated on March 16, 2026 after FTC indicated opposition to the deal. The FTC determined the deal would have combined the two dominant players in femtosecond laser-assisted cataract surgery (FLACS), threatening prices and innovation. LENSAR retained a $10 million deposit. Deal originally signed in March 2025.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
LENSAR competitors and assessment
Company assessmentBroad incumbents
- Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic medical device incumbent offering surgical microscopes, IOLs, and laser systems including VisuMax. While broader in scope, Zeiss is a relevant peer in the premium/refractive cataract surgical equipment market.
- HOYA Corporation: HOYA Surgical Optics supplies intraocular lenses and ophthalmic surgical products used in cataract surgery, serving many of the same ASC and hospital customers as LENSAR with overlapping premium IOL positioning.
- Bausch + Lomb: Bausch + Lomb (Bausch Health) is a diversified ophthalmic device and pharmaceutical company that competes across cataract surgery IOLs, viscoelastics, and surgical instruments, overlapping with LENSAR's customer base of cataract surgeons.
Direct peers
- Alcon: Alcon markets the LenSx femtosecond laser system for cataract surgery, the primary direct competitor to LENSAR's ALLY and LENSAR Laser Systems. The FTC identified Alcon and LENSAR as the two dominant FLACS players in its opposition to the proposed $356-430M acquisition.
- Johnson & Johnson Vision: J&J Vision (part of Johnson & Johnson) sells the Catalys femtosecond laser for cataract surgery, a directly comparable FLACS platform competing head-to-head with LENSAR and Alcon in premium cataract surgery centers globally.
Others
- Nidek: Nidek produces ophthalmic diagnostic devices including the OPD-Scan III that integrates with LENSAR's Streamline. While not a direct FLACS competitor, Nidek is a relevant ecosystem peer in refractive cataract surgical planning.
- Topcon Corporation: Topcon manufactures ophthalmic diagnostic equipment (including the Aladdin biometer that integrates with LENSAR's Streamline software). As an integration partner and adjacent diagnostic device vendor, Topcon is a relevant ecosystem peer.
Regional players
- Glaukos Corporation: Glaukos is a US-focused ophthalmic medical device company specializing in micro-invasive glaucoma surgery (MIGS). While its core focus is glaucoma rather than cataract surgery, it serves many of the same ASC customers and competes for similar ophthalmic capital budgets.
- iCare (Revenio Group): iCare/Revenio provides ophthalmic diagnostic and imaging devices used in cataract and glaucoma workflows. As a smaller international ophthalmic device player, it represents a regional/comparable peer in the broader ophthalmic equipment ecosystem.
Emerging players
- STAAR Surgical: STAAR Surgical specializes in implantable collamer lenses (ICLs/EVO ICL) for refractive vision correction, a smaller ophthalmic player with adjacent refractive surgery technology relevant to LENSAR's premium IOL positioning.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LENSAR social profiles
Digital presenceLENSAR financial estimates
Financial estimateRevenue estimate
Valuation estimate
LENSAR leadership team
Management profileNumber of profiles
Profiles5 records
LENSAR funding detail
Funding detailFunding overview
Funding rounds14 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LENSAR M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LENSAR
What does LENSAR do?
LENSAR designs, manufactures, and sells femtosecond cataract laser systems — the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System — to ophthalmic surgeons and eye surgery centers for refractive cataract surgery. Revenue comes from the sale of these capital equipment systems plus recurring service contracts and consumables tied to an installed base of approximately 440 systems. The company complements its hardware with proprietary imaging and software (Streamline, Cataract Density Imaging, IntelliAxis Refractive Capsulorhexis, Iris Registration) that automate surgical planning and precision.
Is LENSAR a public or private company?
LENSAR is a public company. It is classified as public and is currently operating.
When was LENSAR founded?
LENSAR was founded in 2010. It employs 101 to 250 people.
Where is LENSAR based?
LENSAR is headquartered in Orlando, United States, in the North America region.
How does LENSAR make money?
Two revenue lines are on record. System Sales (Capital Equipment) is the primary driver. The others are recurring Revenue (Service/Consumables).
Who are LENSAR's main competitors?
Broad incumbents on record are Carl Zeiss Meditec, HOYA Corporation and Bausch + Lomb. Direct peers are Alcon and Johnson & Johnson Vision. Others are Nidek and Topcon Corporation. Regional players are Glaukos Corporation and iCare (Revenio Group). STAAR Surgical is listed as an emerging player.
Does LENSAR have an API?
No public API is recorded for LENSAR.
What industry is LENSAR in?
LENSAR's product category is Ophthalmic Surgical Laser Systems. Its primary akta.pro industry code is HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics), with a secondary code of HLAHAJAG, Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance). Its NAICS code is 339115 and its SIC code is 3841.